Tempest Therapeutics Announced Updated Results From The Planned Data Analysis Of An Ongoing Phase 1B/2 Study Of TPST-1120 Combination, Showing Clinical Superiority In Multiple Endpoints Compared To Atezolizumab And Bevacizumab In Hepatocellular Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics has announced updated results from an ongoing Phase 1B/2 study of TPST-1120 combination, showing clinical superiority in multiple endpoints compared to Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.
October 11, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics' ongoing Phase 1B/2 study of TPST-1120 combination shows promising results, potentially boosting the company's stock.
The positive results from the ongoing Phase 1B/2 study of TPST-1120 combination indicate a potential breakthrough in Hepatocellular Carcinoma treatment. This could lead to increased investor confidence in Tempest Therapeutics, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100